Both Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) and Equillium Inc. (NASDAQ:EQ) are Biotechnology companies, competing one another. We will compare their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals Inc.	63.21M	10.46	120.55M	-1.29	0.00
Equillium Inc.	N/A	0.00	13.25M	-0.71	0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Lexicon Pharmaceuticals Inc. and Equillium Inc.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both businesses.

	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals Inc.	-190.71%	0%	-36.2%
Equillium Inc.	0.00%	0%	0%

Liquidity

Lexicon Pharmaceuticals Inc. has a Current Ratio of 2.9 and a Quick Ratio of 2.8. Competitively, Equillium Inc.’s Current Ratio is 1.9 and has 1.9 Quick Ratio. Lexicon Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Equillium Inc.

Analyst Recommendations

Lexicon Pharmaceuticals Inc. and Equillium Inc. Recommendations and Ratings are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Lexicon Pharmaceuticals Inc.	0	0	3	3.00
Equillium Inc.	0	0	0	0.00

$19 is Lexicon Pharmaceuticals Inc.’s average price target while its potential upside is 205.47%.

Institutional and Insider Ownership

Institutional investors owned 0% of Lexicon Pharmaceuticals Inc. shares and 27.1% of Equillium Inc. shares. About 0.32% of Lexicon Pharmaceuticals Inc.’s share are owned by insiders. Comparatively, insiders own roughly 21.3% of Equillium Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Lexicon Pharmaceuticals Inc.	25.14%	45.24%	-7.29%	-39.15%	-20.39%	3.46%
Equillium Inc.	13.92%	-14.33%	-51.67%	0%	0%	-7.72%

For the past year Lexicon Pharmaceuticals Inc. has 3.46% stronger performance while Equillium Inc. has -7.72% weaker performance.

Summary

Lexicon Pharmaceuticals Inc. beats Equillium Inc. on 5 of the 9 factors.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain. The company has license and collaboration agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1 clinical trials for the treatment of acute graft-versus-host disease and asthma. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.